Dronedarone

Brand name: Multaq

Dronedarone is an antiarrhythmic drug introduced into clinical practice in 2009. Structurally, the molecule closely resembles amiodarone. The absence of iodine is a structural feature that likely prevents some of the severe adverse effects associated with amiodarone. Its therapeutic indication is the prevention of recurrent episodes of atrial fibrillation and atrial flutter. However, the efficacy of dronedarone in preventing atrial fibrillation recurrence is inferior to that of amiodarone. Numerous clinical trials conducted in recent years have evaluated the efficacy and safety profile of dronedarone.

In the ATHENA trial, the comparison of dronedarone versus placebo in 4,628 patients with atrial fibrillation demonstrated superiority in several clinical endpoints, including hospitalization rates, cardiovascular mortality, and stroke incidence. Published in 2009, the results of the ATHENA trial offered promising prospects for the therapeutic management of atrial fibrillation. Conversely, the PALLAS trial, conducted in patients with permanent atrial fibrillation and published just two years later, revealed that dronedarone increases mortality, leading to its premature termination. Furthermore, the earlier ANDROMEDA trial (2007), which evaluated patients with heart failure, was also terminated prematurely because dronedarone was found to increase mortality in this cohort.

Following these outcomes, the clinical use of dronedarone is no longer widespread in routine practice.

2026-11-18T22:39:00+00:00